Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Drug analysis

Drug analysis


  • Sort by Name
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products ascending
  • Display 30 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Ampyra

    Read More

    Ampyra is a potassium channel blocker, marketed by Acorda Therapeutics and Biogen, which is

    approved to improve walking ability in multiple sclerosis patients. Although Ampyra’s active molecule

    fampridine (4-aminopyridine) is readily available, by using Elan’s Intestinal Protective Drug Absorption

    System, Acorda has developed a sustained-released oral tablet formulation allowing twice-daily

    dosing.

    January 26, 2016
    Find out more
  • AMT-061

    Read More

    AMT-061 is being developed by uniQure as a gene therapy for hemophilia B patients. The product uses an adeno-associated virus as a vector to deliver the highly active Padua factor IX (fIX) variant, which has eightfold to ninefold greater activity than normal, wild-type fIX.

    May 4, 2018
    Find out more
  • Angiomax

    Read More

    Angiomax is a direct thrombin inhibitor which prevents the formation of fibrin from fibrinogen and the activation of coagulation factor XII.

    April 14, 2016
    Find out more
  • Anoro

    Read More

    GlaxoSmithKline and Theravance (now Innoviva) developed the once-daily inhaled combination, Anoro, consisting of umeclidinium and vilanterol for the treatment of chronic obstructive pulmonary disease (COPD).

    July 31, 2018
    Find out more
  • Apalutamide

    Read More

    Apalutamide (Johnson & Johnson) is an orally available androgen signaling inhibitor. The drug exhibits high binding affinity to the ligand-binding domain of androgen receptor (AR) and subsequently inhibits its nuclear import, as well as its ability to bind to DNA. Apalutamide has a similar mechanism of action to Xtandi (enzalutamide; Pfizer/Astellas).

    January 18, 2018
    Find out more
  • APL-130277

    APL-130277

    Read More

    APL-130277 (Dainippon Sumitomo/Sunovion)  is a sublingual film formulation of apomorphine, a non-ergoline dopamine receptor agonist.

    June 21, 2018
    Find out more
  • Apleway

    Read More

    Apleway (tofogliflozin; Chugai) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism.

    November 7, 2017
    Find out more
  • Aplidin

    Read More

    Aplidin is an intravenous, marine-originated cyclic depsipeptide antitumor agent. The drug, which is

    currently synthesized chemically, was originally isolated from the marine tunicate Aplidium albicans

    (Cuadrado et al., 2003; PharmaMar, 2014).

    September 4, 2014
    Find out more
  • Aptiom

    Read More

    Aptiom is a once-daily oral drug containing eslicarbazepine acetate, a third-generation member of the commonly prescribed first-line dibenzazepine family of anti-epileptic drugs (AEDs), including carbamazepine (first-generation) and oxcarbazepine (second-generation).

    May 23, 2017
    Find out more
  • Aramchol

    Read More

    Aramchol (arachidyl amido cholanoic acid; Galmed) is a conjugate of cholic acid and arachidic acid, and belongs to the synthetic fatty acid bile acid conjugates (FABACs) family. Aramchol inhibits the liver enzyme stearoyl-CoA desaturase 1 inhibitor (SCD1), and as a result fatty acid synthesis is reduced while fatty acid oxidation is increased. Additionally, Aramchol has hypocholesterolemic effects due to the upregulation of ATP-binding cassette transporter 1 (ABCA1). Ultimately, Aramchol causes incomplete SCD inhibition while also being anti-atherogenic.

    July 22, 2019
    Find out more
  • Aranesp

    Read More

    Aranesp (darbepoetin alfa; Amgen/Kyowa Hakko Kirin) is a recombinant human erythropoietin product administered by intravenous or subcutaneous injection, and is indicated for the treatment of anemia in chronic kidney disease and chemotherapy-induced anemia.

    January 11, 2018
    Find out more
  • Arcapta

    Arcapta

    Read More

    Novartis has developed Arcapta (indacaterol; marketed as Onbrez outside the US) for use in its Breezhaler/Neohaler dry-powder inhaler for the treatment of chronic obstructive pulmonary disease (COPD).

    July 31, 2018
    Find out more
  • Aricept

    Read More

    Aricept (donepezil; Eisai/Pfizer) has been the gold standard in the treatment of all stages of
    Alzheimer’s disease for more than a decade.

    September 2, 2016
    Find out more
  • arikayce report

    Arikayce

    Read More

    Arikayce is a formulation of the antibiotic amikacin that uses Insmed’s liposomal delivery system and is under development for the treatment of lung infections caused by NTM.

    September 3, 2018
    Find out more
  • Aristada

    Read More

    Aristada (aripiprazole lauroxil; Alkermes) is a long-acting injectable formulation of the atypical antipsychotic aripiprazole. It was developed by Alkermes using its proprietary LinkeRx technology, which allows the gradual release of aripiprazole molecules and lowers the drug’s frequency of administration.

    March 19, 2018
    Find out more
  • arzerra report

    Arzerra

    Read More

    Arzerra (ofatumumab; Genmab/Novartis) is a fully human immunoglobulin G1 and high-affinity antibody that targets a novel epitope on cluster of differentiation 20 (CD20) on the B-cell membrane.

    January 31, 2019
    Find out more
  • Asciminib

    Read More

    Asciminib (Novartis) is a BCR-ABL-targeted tyrosine kinase inhibitor (TKI) in development by Novartis for Philadelphia chromosome-positive diseases such as chronic myeloid leukemia (CML) and acute lymphoblastic leukemia.

    December 7, 2017
    Find out more
  • aspirin

    Aspirin

    Read More

    Aspirin (acetylsalicylic acid) is a non-steroidal anti-inflammatory drug (NSAID) and antiplatelet that is taken orally and commonly used for the treatment of pain. It is highly genericized and has been available in its present form since 1899, when it was first marketed by Bayer.

    July 2, 2018
    Find out more
  • ATIR101

    Read More

    ATIR101 is an immunotherapeutic delivered as an adjunctive therapy for patients receiving HSCT.

    July 6, 2017
    Find out more
  • Atrasentan

    Read More

    Atrasentan’s Phase III trial is unique including an enrichment period to select responders and those who tolerate the drug for randomization.

    February 2, 2018
    Find out more
  • Atripla

    Read More

    Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Bristol-Myers Squibb) is a single-tablet regimen approved for the treatment of HIV-1 infection.

    June 28, 2019
    Find out more
  • Aubagio

    Read More

    Aubagio is the major active metabolite of Arava (leflunomide), Sanofi’s oral treatment for rheumatoid arthritis, and is a dihydroorotate dehydrogenase (DHODH) inhibitor.

    November 24, 2017
    Find out more
  • Aurora-GT

    Read More

    United Therapeutics is developing a gene therapy product called Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells)

    October 29, 2018
    Find out more
  • Auryxia

    Read More

    Auryxia (ferric citrate; Keryx Biopharmaceuticals/Japan Tobacco/Torii Pharmaceutical) is a novel oral ferric iron form with hematinic activity, approved for the treatment of anemia in chronic kidney disease.

    January 11, 2018
    Find out more
  • avastin report

    Avastin

    Read More

    Avastin (bevacizumab; Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF).

    February 26, 2020
    Find out more
  • Avonex

    Read More

    Avonex is a biological therapy derived from the interferon family, and Biogen’s leading drug for treating relapsing-remitting multiple sclerosis (RRMS).

    November 24, 2017
    Find out more
  • Azeliragon

    Read More

    Azeliragon is an orally available small molecule that acts as an inhibitor of the receptor for advanced glycation endproducts (RAGE).

    September 2, 2016
    Find out more
  • Azilect

    Read More

    Azilect (Teva/Lundbeck/Takeda) contains the pure R-isomer of rasagiline and acts as a selective irreversible monoamine oxidase inhibitor (MAOI), with up to 10 times more potency than selegiline and without metabolizing into amphetamine derivatives.

    June 21, 2018
    Find out more
  • balixafortide

    Read More

    Balixafortide (Polyphor) is a synthetic cyclopeptide derived from polyphemusin that inhibits C-X-C motif chemokine receptor 4 (CXCR4), a G-protein coupled receptor that exclusively binds to its ligand, stromal cell-derived factor-1 (SDF-1).

    February 26, 2020
    Find out more
  • banzel report

    Banzel

    Read More

    Eisai’s Banzel is an oral sodium channel modulator which is structurally different from currently approved anticonvulsants on account of its triazole derivative structure. The drug’s sole approved indication is the adjunctive treatment of seizures…

    May 23, 2017
    Find out more
Page 2 of 21
Page 2 of 21‹1234›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top